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Objectives. This study sought to assess the feasibility, safety
and efficacy of sustained intracoronary delivery of dexamethasone
by a novel polymer-coated eluting stent.
Background. Development of techniques to provide sustained
local drug delivery has focused on polymers as matrices for drug
incorporation and elution.
Methods. A tantalum wire stent was coated with dexamethasone
(0.8 mg) suspended in a matrix of either low (;80 kD) or high
(;321 kD) molecular weight poly-L-lactic acid (PLLA [0.4 mg]).
Uncoated stents, stents coated with PLLA or stents coated with
dexamethasone in PLLA were overexpanded by 30% to the normal
vessel diameter in the coronary arteries of juvenile farm pigs.
Animals were euthanized 28 days later, and neointimal thick-
nesses were measured. Additional pigs underwent placement of
stents coated with high molecular weight PLLA–dexamethasone
for assessment of arterial tissue and serum concentrations of
dexamethasone at 1 h and 1, 2, 10 and 28 days after stent
implantation.
Results. In vitro dexamethasone release occurred over the first
6 days. Stents coated with low molecular weight PLLA produced
an intense inflammatory neointimal response. Stents utilizing the
high molecular weight PLLA were well tolerated within the
coronary vessel during the 28-day experiment. However, dexa-
methasone did not decrease neointimal hyperplasia. Dexametha-
sone concentrations in the arterial tissue were ;300,000-fold
higher than those in the serum 24 h after stent implantation,
remaining ;3,000-fold higher at 28 days.
Conclusions. The eluting stent utilizing high molecular weight
PLLA appeared to be a well tolerated and effective means of
providing sustained, site-specific drug delivery to the porcine
coronary artery wall for at least 28 days.
(J Am Coll Cardiol 1997;29:808–16)
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Local administration of pharmacologic agents directly to the
site of coronary intervention has been advocated as a means of
concentrating drug in the injured arterial tissue to inhibit
restenosis, and several designs of local delivery catheters have
been evaluated in patients and animal models (1). However, a
consistent limitation of these local delivery techniques appears
to be the rapid washout of agents from the arterial wall within
hours or even minutes of administration (2–4). Development
of techniques to reliably provide sustained local drug delivery
has focused on the use of synthetic or biologic polymers as
matrices for drug incorporation and elution (5); a configura-
tion that may be particularly useful within the coronary
vasculature is that of a polymeric or polymer-coated stent.
Given that implantation of conventional stents appears to limit
the elastic recoil and adverse remodeling components of the
restenotic process, the additional influence of antithrombotic
or antiproliferative agents eluted from a delivery stent could
theoretically result in a marked synergistic reduction in the
extent of lumen renarrowing.
Corticosteroids are potent pharmacologic agents that influ-
ence a broad range of cellular activities and may thus be
expected to inhibit many of the pathways to restenosis after
arterial injury (6). Continuous administration of hydrocorti-
sone or dexamethasone, either systemically or locally from
periadventitial polymer matrices, has been shown (7,8) to
reduce reactive intimal hyperplasia in rabbit and rat models of
arterial injury. However, two clinical trials (9,10) failed to
observe a reduction in the incidence of restenosis in humans by
systemic administration of methylprednisolone or prednisone
for 1 or 7 days, respectively. Corticosteroid therapy was not
prolonged further in these trials because of the potential for
adverse systemic effects with this class of agents. This discor-
dance between successful results obtained using prolonged
corticosteroid delivery in animal models and the lack of benefit
with conventional systemic therapy in humans suggest that
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corticosteroids might be useful test agents for local prolonged
drug delivery.
The current study was carried out to evaluate the feasibility,
safety and efficacy of sustained intracoronary delivery of
dexamethasone using a novel polymer-coated eluting stent in
the porcine coronary injury model.
Methods
Dexamethasone eluting stent. The dexamethasone eluting
stent consisted of a 125-mm diameter tantalum wire configured
into a 16-mm long balloon-expandable coil stent (Wiktor,
Medtronic, Inc.) and coated with a monolithic matrix of
poly-L-lactic acid (PLLA) and dexamethasone base (Upjohn)
(Fig. 1). Two different forms of the biodegradable PLLA
polymer (Medisorb Technologies International) were evalu-
ated in separate phases of the experiment: a low molecular
weight polymer of ;80 kD and a high molecular weight
polymer of ;321 kD. A 1% (w/w) solution of PLLA in
chloroform was prepared, in which was formed a 2% (w/w)
suspension of dexamethasone. This mixture was sprayed onto
the stent wires to form the eluting polymer coating by a
proprietary technique. The ratio of dexamethasone to PLLA in
the coating was 2:1, with ;0.8 mg of dexamethasone and
;0.4 mg of PLLA per stent. The thickness of the polymer layer
on the tantalum wire ranged from 14 to 27 mm (mean 20 mm)
for stents coated with low molecular weight PLLA and from 11
to 23 mm (mean 16 mm) for stents coated with high molecular
weight PLLA. This polymer coating was demonstrated by
microscopy to be sufficiently flexible to allow balloon expan-
sion of the coil wire stent without cracking or peeling from the
wire. Stents were mounted on commercial angioplasty balloons
(Prime, Medtronic, Inc.) and sterilized using a conventional
ethylene oxide gas technique.
The kinetics of dexamethasone elution from sterilized
polymer-coated stents were characterized in an in vitro system.
Stents were placed in glass vials and immersed in 100 ml of
phosphate-buffered saline. At time points ranging from 1 to 13
days, dexamethasone concentrations in aliquots of the elution
buffer were measured by ultraviolet spectrophotometry (model
8452, Hewlett-Packard) at 244 nm and converted to cumulative
elution curves. Chemical stability of the dexamethasone
through the coating, drying, sterilization and elution processes
was confirmed by comparing high pressure liquid chromatog-
raphy spectra obtained from dexamethasone samples eluted
from stents with those derived from freshly prepared solutions
of dexamethasone.
Porcine coronary injury model. All studies were carried
out with approval of the Animal Research Committee of the
Cleveland Clinic Foundation and conformed to guidelines of
the American Association for Accreditation of Laboratory
Animal Care.
Normocholesterolemic female juvenile domestic farm pigs
weighing 25 to 35 kg were treated with oral aspirin (325 mg)
beginning 1 day preoperatively and daily thereafter. General
anesthesia was induced with ketamine (22 mg/kg body weight)
by intramuscular injection and isoflurane inhalation. Using
sterile surgical technique, the right or left carotid artery was
cannulated with an 8F hemostatic sheath through a midline
cervical incision. Heparin (300 U/kg) was administered
through the arterial sheath, and baseline coronary angiography
was performed.
The study was performed in two phases: first with stents
coated with low molecular weight PLLA and then with stents
coated with high molecular weight PLLA. For each phase, pigs
were randomly assigned to receive uncoated stents (control
group), stents coated with PLLA polymer only (PLLA control
group) or stents coated with PLLA and dexamethasone
Figure 1. Top, Uncoated control Wiktor tan-
talum coil wire stent. Bottom, Eluting stent
coated with high molecular weight poly-L-
lactic acid and dexamethasone.
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(PLLA–dexamethasone group) (Fig. 2). One stent was placed
within each of the three major epicardial arteries. All coronary
segments within a given animal were injured with the same
type of stent to avoid the potential confounding influence of
drug delivered into the systemic circulation from the stent.
Using the known dimensions of the angiographic catheters as
a scaling device, suitable vascular segments were chosen to
allow placement of 3.0- to 4.0-mm diameter stents intentionally
overexpanded by a 1.3:1 ratio to the normal coronary lumen
diameter (2.3 to 3.1 mm) to produce the characteristic vascular
injury (11). Stents were deployed by a single balloon inflation
to 6 atm for 30 s. Angiography was repeated to confirm
adequate stent expansion and vessel patency.
The carotid arteriotomy site was ligated and the neck
wound closed with layered interrupted sutures. Animals were
maintained on a standard laboratory chow diet throughout the
study period and received antibiotic prophylaxis with ampicil-
lin (250 mg orally) twice daily.
Histologic analysis of neointimal hyperplasia. Follow-up
angiography was performed 28 days after stent implantation
under general anesthesia. Pigs were then euthanized by over-
dose of intravenous pentothal and hearts removed and perfu-
sion fixed at 70 mm Hg for 24 h with 4% neutral buffered
formalin. Stented coronary artery segments were located,
removed and sectioned at 2-mm intervals perpendicular to the
vessel axis using sharp, hardened scissors to divide the tanta-
lum stent wires. Stent wire fragments were carefully removed
using a dissecting microscope, and 2-mm arterial segments
were embedded in paraffin blocks, sectioned and stained with
hematoxylin-eosin and Lawson’s elastic-van Gieson. Polymer
coatings on the stent wire fragments were evaluated by elec-
tron microscopy at Medtronic, Inc.
All coronary segments were qualitatively inspected by an
observer (A.M.L.) blinded to treatment regimen for the pres-
ence of thrombosis, inflammation or other tissue response and
to assess the depth of vascular stent injury by stent wires. The
segment demonstrating the most severe degree of lumen
stenosis was selected for quantitative morphometric analysis
using a computerized digital microscopic planimetry algorithm
(Image-1/MetaMorph, Universal Imaging Corporation).
Quantitative histologic analysis of stent-injured vessels was
performed according to the technique described by Schwartz et
al. (11–13). At every stent wire site (typically three to five
visible per cross-sectional segment), neointimal thickness over-
lying the wire was measured along an orthogonal line from the
stent wire to the lumen surface. The depth of vessel wall injury
by the oversized stent (the stimulus for neointimal formation)
at every wire site was also determined and assigned a numeric
injury score (0 5 internal elastic lamina intact; 1 5 internal
elastic lamina lacerated; 2 5 internal elastic lamina and media
lacerated; 3 5 external elastic lamina lacerated). A mean
neointimal thickness and a mean injury score were calculated
for all wire sites within each coronary segment (11–13).
Quantitative assessment of local dexamethasone delivery.
In a separate group of 10 pigs, the kinetics of dexamethasone
delivery to the arterial wall were assessed (Fig. 2). Overex-
panded stents coated with high molecular weight PLLA and
dexamethasone were placed in three coronary vessels of each
pig, as previously described. At each of five different time
points after stent implantation (1 h and 1, 2, 10 or 28 days), two
animals underwent measurement of dexamethasone concen-
trations in the serum and stented vascular tissue. Stented
coronary segments were trimmed to exclude periadventitial
tissue and arterial tissue proximal or distal to the stent. Each
vascular segment was opened longitudinally and the stent
removed, with care taken not to dislocate overlying neointimal
tissue. Segments were washed with 20 ml of normal saline,
blotted dry, weighed, snap-frozen in liquid nitrogen and stored
at 2708C. Dexamethasone concentrations in the serum and
vascular tissue at the various time points were measured at a
commercial reference laboratory (Endocrine Sciences, Calaba-
sas Hills, California).
The “efficiency” of dexamethasone transfer from the eluting
stent to the arterial wall was estimated from vascular tissue
Figure 2. Experimental protocol. PLLA 5 poly-L-lactic
acid.
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concentrations of dexamethasone and in vitro release kinetics
data. The vessel wall geometry was simplified with the assump-
tions of an cylindrical artery with a lumen diameter of 3.75 mm
(mean of the 3.5- and 4.0-mm stents used in this phase of the
experiment), a length of 16 mm (the length of the implanted
stent) and a vessel wall thickness of 1 mm. The density of
arterial tissue was assumed to be 1 g/cm3.
Statistical analysis. Continuous variables are expressed as
mean value 6 SD. Dexamethasone concentrations in tissue or
serum at the various time points were compared by analysis of
variance with the Bonferroni adjustment. A p value ,0.05 was
considered significant.
Differences between treatment groups with regard to the
extent of neointimal hyperplasia occurring during the 28 days
after stent implantation were assessed as follows. The mean
injury score (stimulus) and mean neointimal thickness (re-
sponse) may be related by linear regression to calculate a slope
and intercept (11–13). A reduction in the neointimal prolifer-
ative response to vessel injury due to therapy would result in a
decrease in the slope or the intercept of this regression
relation, or both. Thus, these slope and intercept values serve
as end points for comparing study groups. Linear regression
analysis for mean neointimal thickness versus mean injury
score was performed using arterial segments obtained from all
three study groups (uncoated control stents, PLLA control
stents and PLLA–dexamethasone stents). Binary variables GP
and GD (value 0 or 1) representing implantation of PLLA
control or PLLA–dexamethasone stents, respectively, were
added to the regression equation to evaluate whether either
stent coating produced a statistically significant change in slope
or intercept. The following regression equation was used:
Mean neointimal thickness 5
@Slope 1 ~aP 3 GP! 1 ~aD 3 GD!# 3
Mean injury score 1 Intercept 1 ~bP 3 GP! 1 ~bD 3 GD!,
where aP and aD are the coefficients of the slope and bP and
bD the coefficients of the intercept estimated by multiple
regression. A statistically significant effect of either stent
coating on the slope of the linear relation between neointimal
thickening and injury score was established if the p value for aP
or aD was ,0.05. A significant effect of stent coating on the
intercept of the linear relation was established if the p value for
bP or bD was ,0.05.
Among the pigs in phase 1 of the experiment, in which an
inflammatory response to the stents coated with low molecular
weight PLLA obscured normal vascular wall boundaries and
rendered assessment of injury score impossible, quantitative
comparison between treatment groups was not performed.
Results
Phase 1: low molecular weight PLLA stents. In vitro elu-
tion of dexamethasone from three sample stents coated with
low molecular weight (;80 kD) PLLA polymer over 11 days is
shown in Figure 3 (top). More than 50% of dexamethasone
elution occurred within the first 2 to 3 days, with a leveling off
of the elution curves after 6 to 7 days.
Fifteen pigs underwent implantation of 44 stents (five
animals in each of the three study groups). Four animals died
before the scheduled 28-day euthanasia: one with fever and
presumed sepsis 9 days postoperatively in the uncoated control
stent group, one of stent thrombosis in the PLLA control stent
group (2 h postoperatively) and two of stent thrombosis in the
PLLA–dexamethasone stent group (2 and 21 days postopera-
tively). Necropsy studies of animals dying of stent thrombosis
demonstrated occlusive or partially occlusive thrombosis in all
coronary stents. A total of 32 stented vessels (12 uncoated
control, 11 PLLA control, 9 PLLA–dexamethasone) were
available for evaluation.
Gross examination of stented coronary segments revealed a
thin layer of neointimal tissue overlying uncoated control stent
wires. However, in PLLA control stent segments, the vessel
lumen was nearly obliterated (Fig. 4), whereas arteries injured
with the PLLA–dexamethasone stents exhibited a degree of
neointimal thickening that was intermediate between that
induced by uncoated control and PLLA control stents. Micro-
scopic examination of the coronary segments injured with
uncoated control stents demonstrated a proliferative neoin-
tima consisting of a uniform population of spindle-shaped cells
in an extracellular matrix. In contrast, a severe cellular inflam-
Figure 3. Cumulative (mean 6 SD) in vitro dexamethasone elution
from poly-L-lactic acid (PLLA)–dexamethasone-coated stents over
12-day period. Top, Low molecular weight PLLA (three stents).
Bottom, High molecular weight PLLA (five stents).
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matory response was observed in all arteries in which PLLA
stents were deployed, consisting of mononuclear cells, lympho-
cytes and multinucleated giant cells concentrated at the poly-
mer–tissue interface. Normal vessel architecture was variably
destroyed, with lysis of the elastic laminae and severe lumen
stenosis.
Phase 2: high molecular weight PLLA stents. In vitro
elution curves of dexamethasone from five sample stents
coated with high molecular weight (;321 kD) PLLA are
shown in Figure 3 (bottom). More than 50% of dexamethasone
elution occurred within the initial 1 to 2 days, with a leveling off
of the elution curves by 6 days.
Fifteen pigs underwent placement of 45 stents in phase 2 of
the study (five animals in each of the three study groups). One
animal in the PLLA control group died of excessive stent
overexpansion, coronary occlusion and ventricular fibrillation
immediately after stent implantation. A total of 42 stented
segments (15 uncoated control, 12 PLLA control, 15 PLLA–
dexamethasone) in 14 animals surviving to 28-day euthanasia
were analyzed.
Electron micrographs of PLLA–dexamethasone stent wire
coatings before deployment and at explantation from the
porcine coronary vessels are shown in Figure 5. Dexametha-
sone crystals were visible dispersed within the high molecular
weight PLLA matrix before elution. By 28 days after implan-
tation, the dexamethasone crystals had dissolved and were no
longer visible, although the polymer matrix appeared largely
intact.
All stented vessels were patent, with moderate stenoses by
angiography, before 28-day euthanasia. In contrast to the
findings with the low molecular weight PLLA stent coatings,
vessels injured by stents coated with high molecular weight
Figure 4. Photomicrographs of arterial cross sec-
tions at 28-day euthanasia after injury with low
(top) and high molecular weight poly-L-lactic acid
(PLLA) control stents (Bottom). Hematoxylin-
eosin stain; 38, reduced by 35%.
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PLLA exhibited no evidence of acute or chronic inflammation.
Neointimal tissue overlying PLLA control or PLLA–
dexamethasone stents was identical in appearance to that
forming in response to injury by the uncoated control stents,
consisting of smooth muscle cells and extracellular matrix
without inflammatory cells (Fig. 4).
Results of the quantitative morphometric analysis are dis-
played in Figure 6, with mean neointimal thickness as a
function of mean injury score. The linear relation between
neointimal thickness and injury score was highly significant by
linear regression for arterial segments from all three study
groups (R2 5 0.568, p , 0.0001), and neointimal responses to
injury by PLLA control and PLLA–dexamethasone stents
were superimposable on uncoated control stent values. The
PLLA or PLLA–dexamethasone stent coatings thus produced
no significant change in the neointimal hyperplastic response
to injury (Table 1).
Quantitative assessment of dexamethasone delivery.
Dexamethasone concentrations within arterial tissue (ng/mg
wet tissue weight) and serum (ng/ml serum) at the five time
points evaluated after implantation of high molecular weight
PLLA–dexamethasone stents are displayed in Figure 7. Tissue
and serum concentrations were compared by assuming arterial
tissue density equal to that of serum. By 1 h after stent
deployment, the mean dexamethasone concentration within
the adjacent arterial tissue was 250 6 202 ng/mg, whereas the
mean serum dexamethasone concentration was nearly five
orders of magnitude lower at 0.00278 6 0.00106 ng/ml. Tissue
concentrations of dexamethasone increased slightly by 1 day
(329 6 285 ng/mg, p 5 NS vs. 1 h) and decreased thereafter
(54.8 6 45.8 ng/mg at 2 days, p 5 0.059 vs. 1 day; 0.850 6
0.804 ng/mg at 10 days, p 5 0.014 vs. 1 day; 0.517 6 0.581
ng/mg at 28 days, p5 0.014 vs. 1 day). Serum concentrations of
dexamethasone progressively declined after 1 h (0.00104 6
0.001 ng/ml at 1 day, p 5 0.174 vs. 1 h; 0.00056 6 0.00033 ng/ml
at 2 days, p 5 0.073 vs. 1 h; 0.00040 6 0.00007 at 10 days, p 5
0.054 vs. 1 h; 0.00015 6 0.00022 ng/ml at 28 days, p 5 0.036 vs.
1 h). Even by 28 days after stent implantation, dexamethasone
concentrations in the arterial wall remained .3,000-fold
higher than those in the serum.
Using the idealized assumptions of cylindrical vessel wall
geometry and in vitro elution detailed in the Methods section,
it was estimated that 8% and 10% of the total dexamethasone
initially contained within the stent coating was present in the
arterial wall by 1 and 24 h after implantation, respectively.
Moreover, of the estimated 370 mg of dexamethasone that had
been eluted from the stent by 24 h, 21% was retained within
the arterial wall.
Discussion
A drug-eluting stent consisting of a PLLA polymer over a
metal backbone was developed and evaluated using dexameth-
asone as a test agent in the porcine coronary injury model.
Stents coated with the low molecular weight form of this
Figure 5. Electron micrographs of high molecular weight poly-L-lactic
acid–dexamethasone stent coatings before (top, 31,000 [reduced by
30%]) and 28 days after implantation (bottom, 31,100 [reduced by
30%]) in porcine coronary arteries. Dexamethasone crystals visible
before elution (arrow) are no longer present after 28 days, although
polymer matrix appears largely intact.
Figure 6. Quantitative morphometric analysis of relation between
mean neointimal thickness and mean injury score at 28-day euthanasia
for the second phase of study. There are no differences between study
groups. Control 5 uncoated control stent (n 5 15). PLLA 5 high
molecular weight poly-L-lactic acid control stent (n 5 12); PLLA-
DEX5 high molecular weight poly-L-lactic acid–dexamethasone stent
(n 5 15).
Table 1. Linear Regression Analysis of Morphometric Results for
Phase 2 High Molecular Weight Poly-L-Lactic Acid Stents*
PLLA Control Stents PLLA–Dex Stents
Coeff p Value Coeff p Value
Alpha (slope) 20.221 0.386 0.262 0.280
Beta (intercept) 0.451 0.433 20.444 0.389
*Slope 5 0.611 mm; intercept 5 20.527 mm; p , 0.0001; R2 5 0.568.
Coeff 5 coefficient; Dex 5 dexamethasone; PLLA 5 Poly-L-lactic acid.
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biodegradable polymer produced an intense inflammatory
neointimal response by 28 days after implantation. However,
stents utilizing the high molecular weight form of PLLA
appeared to be well tolerated within the coronary vessel during
the 28-day experiment, with no evidence of associated cellular
inflammation. The concentration of dexamethasone in the
arterial tissue treated with the eluting stent was found to be
90,000- to 300,000-fold higher than that in the serum during
the first day after stent implantation, remaining 3,000-fold
higher even after 28 days. Nevertheless, dexamethasone at the
dose administered locally in this experiment did not decrease
neointimal hyperplasia in the porcine coronary artery after
stent overexpansion injury.
Local drug delivery and residence time. Several investiga-
tors have observed that drugs are typically lost from the
intramural site rapidly after local administration by delivery
catheters. Vascular wall concentrations of labeled heparin,
urokinase and hirudin have been documented to decline by as
much as 92% within only 30 to 90 min of delivery by hydrogel
balloons (14), the Dispatch catheter (3) or iontophoresis (15).
Polymeric implants may be useful as vehicles to provide
sustained local elution and delivery of therapeutic agents to the
arterial wall. Polymers containing heparin (16), antisense
oligonucleotides (17) or dexamethasone (8) surgically im-
planted in a periadventitial position in small-animal models
have been demonstrated to reduce reactive neointimal hyper-
plasia and prolong tissue uptake of drug after experimental
arterial injury. However, although useful for providing “proof
of concept” of the efficacy of sustained local drug delivery, such
periadventitial delivery systems are not practical for human
applications after percutaneous coronary revascularization.
Drug-eluting stents. Polymer stents composed of polyeth-
ylene terephthalate (18) or PLLA (19) or metal stents coated
with polyurethane or the biologic polymer fibrin (20) have
been tested for biocompatibility in porcine and canine models,
although the usefulness of these designs for drug delivery has
not yet been reported. Stents coated with cellulose ester
polymer were used to deliver heparin or methotrexate, or both,
in the porcine coronary injury model (21), demonstrating
apparent biocompatibility over 28 days but no therapeutic
effect on reduction of neointimal hyperplasia. Drug delivery to
the arterial tissue was not assessed in that study. Lambert et al.
(22) utilized a nitinol metal stent coated with a polyurethane to
deliver forskolin to the rabbit carotid artery. More than 95% of
the forskolin was eluted from the stent coating during the first
24 h after deployment. Arterial wall concentrations of forsko-
lin were demonstrated to increase to 460-fold greater than that
in the blood by 4 h after implantation, but local tissue levels
declined to 77-fold greater than blood concentrations by 24 h.
Acute biologic activity of the forskolin released from the stent
was documented by changes in carotid blood flow and prolon-
gation of the time to arterial occlusion after crush injury.
Long-term biocompatibility or drug delivery with this stent
.24 h was not evaluated.
To our knowledge, the current study is the first to demon-
strate the feasibility of local delivery through a percutaneously
implanted eluting stent to provide a drug residence time within
the injured arterial tissue ($28 days) that would be relevant for
the clinical prevention of restenosis. This delivery stent utilized
a monolithic matrix coating of dexamethasone within PLLA.
Although PLLA is a biodegradable polymer, hydrolysis in vivo
typically occurs over a period of months to years, particularly
with the high molecular weight forms (23). Thus, the primary
mechanism of dexamethasone release during the 28-day course
of this experiment was most likely diffusion of drug through the
pores of the polymer. Electron microscopic examination of
stent coatings after explantation confirmed that the polymeric
matrix was grossly preserved, with disappearance of the dis-
persed dexamethasone crystals. Although elution studies sug-
gested that nearly all the dexamethasone was released from the
high molecular weight PLLA stents within 6 days in vitro, drug
delivery appeared to be substantially more prolonged within
the coronary artery. Dexamethasone levels were measurable
within both arterial tissue and serum for 28 days, although both
concentrations fell by two or three orders of magnitude over
that time period. Despite the fact that drug release from the
stents in vivo was not directly measured in this experiment, it
can be inferred from these concentration data and the 2- to 5-h
plasma half-life of dexamethasone (24) that elution from these
stents may have continued for at least 28 days. Alternatively,
the lipophilic properties of the dexamethasone molecule may
have prolonged its retention within the arterial tissue, thus
exaggerating the apparent duration of delivery from the stent.
On the basis of in vitro elution kinetics and dexamethasone
arterial tissue concentrations, it is estimated that 21% of the
dexamethasone released from the stent within the first 24 h was
delivered to the arterial wall. The remaining dexamethasone
either diffused regionally from the coronary artery to the
surrounding myocardium or was released into the blood. It is
difficult to compare different techniques for local drug delivery
assessed in separate studies utilizing agents of varying solubil-
ities or molecular weights. Nevertheless, the extent of drug
Figure 7. Semilogarithmic plot of dexamethasone concentrations in
stented arterial tissue (ng/mg wet tissue weight [circles]) and serum
(ng/ml serum [triangles]) at five time points after implantation of three
high molecular weight poly-L-lactic acid–dexamethasone stents in
coronary arteries of each pig. At each time point, two serum samples
and six stented vascular tissue samples were obtained from two pigs.
For comparison, plasma concentrations of dexamethasone 1 h after
intravenous administration of a 1-mg dose in humans range from 0.01
to 0.1 ng/ml (24).
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transport into the arterial wall by the eluting stent compares
quite favorably with the various designs of local delivery
balloon catheters, for which transfer efficiencies of 0.01% to
3% are typically reported (3,25–27). The extraordinarily high
concentration gradient of dexamethasone between the arterial
wall and the blood, ranging from 300,000-fold at 1 day to
3,000-fold at 28 days, suggests that the eluting stent may be
particularly useful for achieving local therapeutic tissue con-
centrations of agents that have systemic toxicity. However,
these estimates of dexamethasone transport are subject to two
potential limitations: 1) Because a reservoir of delivered
dexamethasone within the periadventitial space cannot be
ruled out, the removal of periadventitial tissue from the vessels
in our experiment could have led to an underestimation of the
total quantity of dexamethasone delivered to the vascular
tissue. 2) The presence of residual polymeric stent coating on
the vessel surface after removal of the stents could not be
excluded, despite careful removal of the stent wires and
extensive washing of the tissue before analysis; such residual
stent coating would have led to an overestimation of drug
delivery.
Intravascular biocompatibility. For a polymer to be useful
as an intravascular delivery device, compatibility at the blood/
tissue interface must be ensured. Previous reports (18,20,28)
have in fact suggested that tissue incompatibility may be a
major obstacle in the development of polymeric stents for
intracoronary drug administration. Variable degrees of accel-
erated thrombosis and inflammatory responses have been
observed with a number of biostable or biodegradable poly-
mers implanted within the porcine coronary vasculature.
The polymer evaluated in the current study (PLLA), has
been utilized for orthopedic applications in humans and has
generally been found to be biocompatible for at least the first
few weeks to months after implantation (29–31). In the first
phase of the present study, stents coated with low molecular
weight PLLA produced an unequivocal inflammatory reaction
within the vascular wall. In contrast, no adverse tissue response
was induced over 28 days after implantation of stents coated
with high molecular weight PLLA in the second phase of the
experiment. Explanations for the observed differences in tissue
responses to the two forms of PLLA in this study are specu-
lative but may relate to the prolongation of the biodegradation
time with increasing molecular weight (23). It has been sug-
gested (32,33) that the degradation products of PLLA may
play a causative role in tissue inflammation, and a slow erosion
rate might thus minimize the concentrations of these degrada-
tion products. However, under these circumstances, the poten-
tial exists for late development of inflammation as the high
molecular weight PLLA hydrolyses. Importantly, then, long-
term biocompatibility studies with this stent over a period of
several months would be required before permanent implan-
tation in humans could be considered.
Corticosteroids for prevention of restenosis. Studies in
animal models or with tissue from human coronary lesions
have suggested (34,35) that infiltration of monocytes and other
inflammatory cells, with release of mitogenic and chemotactic
factors, may play a role in the pathogenesis of atherosclerosis
and restenosis. Glucocorticoids exert a profound inhibitory
effect on these inflammatory processes (6) and may also
influence platelet function (36), smooth muscle cell prolifera-
tion (7) and collagen synthesis (37). Continuous infusion of
hydrocortisone over a 2-week period in rabbits subjected to
aortic balloon injury resulted in a significant reduction in
neointimal hyperplasia in one study (7). Marked inhibition of
neointimal hyperplasia was also achieved in the rat carotid
injury model by local delivery of dexamethasone from
sustained-release periadventitial polymer matrices (8) or en-
doluminal nanoparticles (38).
Despite prolonged delivery of dexamethasone to the in-
jured porcine coronary artery by the eluting stent in the current
study, neointimal hyperplasia was not reduced by 28 days,
although early suppression of neointimal formation, followed
by “escape” from inhibition cannot be excluded. The failure of
dexamethasone to influence the vascular response to injury in
this model may be related to interspecies variability in the
pathogenesis of neointimal hyperplasia or differences in the
mechanisms of arterial injury. These findings suggest that
inflammatory responses, which would have been expected to
be suppressed by dexamethasone, may not in fact moderate a
key pathway to restenosis, at least in the porcine model of stent
arterial injury. Although it is also possible that tissue levels of
dexamethasone in the present study may have been inadequate
to produce a therapeutic effect, the concentrations of dexa-
methasone achieved with this eluting stent were comparable to
those obtained in previous studies using periadventitial deliv-
ery systems. Reductions in neointimal hyperplasia in the rat
carotid injury model (8) were demonstrated using periadven-
titial polymer matrices that produced a concentration of
dexamethasone in the arterial wall 14 days after implantation
of 0.880 6 0.220 ng/mg tissue (vs. 0.850 6 0.804 ng/mg tissue
at 10 days after placement of the eluting stents in the current
study). Moreover, treatment of injured porcine carotid arteries
with periadventitial polymers containing dexamethasone in
another study (39) failed to inhibit neointimal hyperplasia,
despite arterial wall concentrations of 1.307 6 0.498 ng/mg
tissue 5 days after implantation.
Conclusions. A drug-eluting stent was developed that con-
sists of a tantalum metal wire coated with dexamethasone
dispersed within a monolithic matrix of high molecular weight
PLLA biodegradable polymer. This stent was demonstrated to
be a well tolerated and effective means of providing sustained
site-specific drug delivery to the porcine coronary artery wall
for 28 days, although longer term biocompatibility of the
polymer coating was not assessed. Dexamethasone did not
reduce the neointimal hyperplastic response to injury, despite
sustained tissue levels of drug. If subsequent studies confirm
the biocompatibility of the polymer coating over longer peri-
ods of time within the coronary vasculature, this eluting stent
may prove to be useful for the prevention of restenosis using
other pharmacologic agents.
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